Leading institutions use
the OncoDiscover® Tests
OncoDiscover® Tests are being widely accepted by the oncology fraternity and is used for monitoring and effective therapy decisions.
.jpg)
Fighting cancer.
One cell at a time.
One in a billion cells.
Even a single tumor cell can cause cancer relapse and can lead to metastasis (spread of cancer). OncoDiscover® Tests detect, with pinpoint accuracy, those pesky cells whose presence, even a single one of them, leads to the spread of cancer even after the patient’s treatment has been completed and the patient seems to have recovered.
Cost-effective
The OncoDiscover® Tests has been developed with a goal of making it affordable and accessible to everyone who is in need of it. It is 50% cheaper than any other test to diagnose cancer cells.
Time Saving
At OncoDiscover® laboratory the diagnostic test are run on the blood samples of the patients. Typically a complete run cycle is completed within a weeks time followed by analysis by scientific experts.
Accurate
The OncoDiscover® Tests can identify pesky tumor cells amongst billions of cells in the blood samples from the patients. It is as accuarate as counting one in a billion cells from the blood sample.
Safe
The OncoDiscover® Tests is absolutely safe. Only patients blood sample is collected and subject to the diagnostic runs. Patients don’t need to through any other tests including that involving radiations.
Convenient
The OncoDiscover® Tests is a simple blood test. Just book the Test online or through a phone call. Our registered phlebotomists can collect the blood samples from patient’s home.
Pain-free
The patient doesn’t have to go through any medical procedure or go through any tissue biopsy. All that it needs is patients blood samples - ensuring its physically and emotionally pain-free for the patient.
Accreditations/ Patents
CDSCO Approved
License No.
MFG/IVD/2019/000031
ISO Certified Lab
ISO 13485:2016 certified by INTERTEK;
Certificate No. 0140783
NABL Certified Lab
Certificate No.
NABLM0726MH08160
Patented
International Application No.
PCT/IB2016/050779
Our
Publications
In collaboration with researchers and thought leaders around the world, OncoDiscover® Team combines scientific expertise with cutting-edge innovation to advance the frontiers of cancer care. The research behind the technology is supported by 100+ scientific publications presented at leading global forums such as ASCO, AACR, ESMO, ISLB, etc
1 Sept 2026
Longitudinal Assessment of Circulating Tumor Cells Expressing PD-L1 and Clusters in Esophageal Cancer Patients
A longitudinal study of 110 esophageal cancer patients evaluated CTCs, PD-L1 expression, and CTC clusters, highlighting their potential as predictive biomarkers for treatment outcomes and occult minimal cellular residual disease.
30 Aug 2026
Evaluation of circulating tumor cells expressing PD-L1 and CTC clusters at baseline and follow ups in triple-negative breast cancer
A retrospective study of 180 TNBC blood samples evaluated CTC burden, PD-L1 expression and CTC clusters using the CDSCO-approved OncoDiscover platform, highlighting their potential for longitudinal disease monitoring and biomarker-guided management.
30 Aug 2026
Assessment of apprehension for Minimal Cellular Residual Disease Using Circulating Tumour Cells in Pre and Post Surgery Breast Cancer Patients
A prospective study evaluates RUPIKA, a structured CTC-based MRD disclosure protocol, showing significantly reduced cancer worry among breast cancer patients after surgery compared with routine result communication.
Be informed.
Be a fighter.
Sharvari Pantekar
Breast Cancer Survivor
Rupali Gunjikar
Neuro-endocrine Cancer Survivor
What’s More Painful than a Cancer Relapse
A cancer Relapse not Caught in Time.
14 Mar 2026
Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control
Actorius Innovations and Research Pvt Ltd, a pioneering Indo-US biotechnology company revolutionizing oncology through advanced circulating tumor cell (CTC) technologies, continues to make significant strides under the visionary leadership of Dr. Jayant Khandare, Founder, Managing Director, and Chief Scientific Officer.
Early detection is half the battle won.
Book a Test
Simply book a Test online or over a phone call and schedule a visit by our registered phlebotomists.
Sample Collection
Upon booking the Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample.
Receive Report
A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site.